• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Patient-reported physical function has ‘real clinical value’ for treating multiple myeloma

by Josh Friedman | Jul 7, 2025 | Uncategorized

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who reported having “low” physical function, such as struggling to do...

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

by MM360 Staff | Jul 3, 2025 | Uncategorized

Source: CureToday articles The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program. Read More

FDA accelerates linvoseltamab-gcpt approval for multiple myeloma

by Lucas Laboy | Jul 2, 2025 | Uncategorized

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome...

What Should Patients with Multiple Myeloma Know After ASCO 2025?

by MM360 Staff | Jun 27, 2025 | Uncategorized

Source: CureToday articles Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting. Read More

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

by MM360 Staff | Jun 26, 2025 | Uncategorized

Source: CureToday articles I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection. Read More

You Are Not Alone While Building a Support Team During Cancer Care

by MM360 Staff | Jun 9, 2025 | Uncategorized

Source: CureToday articles Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship. Read More
« Older Entries
Next Entries »

Recent Content

  • Outcomes of relapse after teclistamab therapy in multiple myeloma
  • Canada agency backs coverage of new ovarian cancer drug
  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT